CJC-1295 (No DAC) / IpamorelinCheck methods and identity
What a combination label can establish about the material inside
3 numbered sourcesSource years 2024, 2026
Peptides are short amino-acid chains linked by peptide bonds. They can imitate biological signals, and changes to either chain in a mixture can matter to how that mixture behaves. CJC-1295 (No DAC) / Ipamorelin names a 29-residue modified growth hormone–releasing factor and a separate five-residue agonist of the ghrelin receptor. Which parts of that identity can a catalog label establish? [1, 2]
An April 2026 advisory from Australia's Therapeutic Goods Administration listed products containing CJC-1295 among examples of unapproved peptide goods. The agency described uncertainty about the ingredients, manufacturing and sterility of such products, and pointed out that labels can be inaccurate. The advisory addressed a regulatory category of products. It did not report a chemical analysis of a specific no-DAC and ipamorelin preparation. [3]
The FDA's older substance assessments explain a distinction behind the names. The no-DAC form lacks the drug affinity complex that is attached to the longer-acting CJC-1295 molecule. Ipamorelin and its acetate salt were evaluated as separate bulk substances. A label naming the two intended active peptides leaves open the exact chemical forms, the amount of each and whether the preparation contains other substances or degradation products. [1, 2]
No recent primary study identifying and following the two compounds in the exact catalog mixture was identified. Chemical characterization could verify what is present in a tested sample, while a controlled biological experiment would answer a different question about its effects. The regulatory records cover the quality and evidence issues they reviewed. They provide no independent verification of the contents or clinical performance of this pairing. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
